MGC Pharma now owns one of the most advanced cannabis production facilities in Europe after securing …

    0
    173

    Special Report: Medical cannabis developer MGC Pharma has hit another milestone in its quest to bring innovative pharmaceutical grade medicinal cannabis products to the globe, securing a Manufacturing License for its European GMP cannabis production facility. The awarding of this formal manufacturing license signifies compliance with strict European quality standards for production and manufacturing of pharmaceutical grade products and the handling of cannabis based medicines. Email ListsMorning UpdateLunch Update The ASX-traded medical cannabis biopharma company (ASX:MXC) has gained the license in another milestone in solidifying the pipeline for its global seed to pharma goal. The first product to emerge for patients from this pipeline is CannEpil™, a phytocannabinoid-based medication for the treatment of refractory epilepsy, which will soon be in patient’s hands in Australia through the Authorized Prescriber Scheme. This Manufacturing License means MGC will able to start full-scale manufacturing for the CannEpil™ product but also permits MGC to produce additional medicinal cannabis based pharmaceutical products, for use in the clinical studies, research pipelines and product development. These products will be distributed into the global market and target the increasing demand for medicinal cannabis pharmaceutical products. MGC Pharma now owns one of the most advanced cannabis production facilities in Europe after securing …

    thumbnail courtesy of stockhead.com.au

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here